Pre-made Nurulimab benchmark antibody ( Whole mAb, anti-CTLA4/CTLA-4 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Nurulimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nurulimab (also known as BCD 145) is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for the treatment of cancer
| Products Name (INN Index) | Pre-Made Nurulimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody |
|---|---|
| INN Name | Nurulimab |
| Target | CTLA4 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | 5xj3:AB/5tru:HL/6jc2:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Biocad |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Malignant melanoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CTLA4 |
| Package |
